DOCSLIB.ORG

(12) Patent Application Publication (10) Pub. No.: US 2014/0190496 A1 Wensley Et Al

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
(12) Patent Application Publication (10) Pub. No.: US 2014/0190496 A1 Wensley Et Al US 2014O190496A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2014/0190496 A1 Wensley et al. (43) Pub. Date: Jul. 10, 2014 (54) METHODS AND DEVICES FOR COMPOUND filed on Mar. 15, 2013, provisional application No. DELIVERY 61/831,992, filed on Jun. 6, 2013, provisional applica tion No. 61/887,045, filed on Oct. 4, 2013. (71) Applicant: E-NICOTINE TECHNOLOGY, INC., Draper, UT (US) Publication Classification (72) Inventors: Martin Wensley, Los Gatos, CA (US); (51) Int. Cl Michael Hufford, Chapel Hill, NC we (US); Jeffrey Williams, Draper, UT A24F 47/00 (2006.01) (US); Peter Lloyd, Walnut Creek, CA (52) U.S. Cl. (US) CPC .................................... A24F 47/008 (2013.01) USPC ........................................... 131/273; 131/328 (73) Assignee: E-NICOTINE TECHNOLOGY, INC., Draper, UT (US) (57) ABSTRACT (21) Appl. No.: 14/092,405 Provided herein are methods, devices, systems, and computer (22) Filed: Nov. 27, 2013 readable medium for delivering one or more compounds to a O O Subject. Also described herein are methods, devices, systems, Related U.S. Application Data and computer readable medium for transitioning a Smoker to (60) Provisional application No. 61/730,738, filed on Nov. an electronic nicotine delivery device and for Smoking or 28, 2012, provisional application No. 61/794,601, nicotine cessation. A O A-Cl Patent Application Publication Jul. 10, 2014 Sheet 1 of 26 US 2014/O190496 A1 102 sts ss : X:X.8 : 8 8: X. y 2O2 KXXXXXXXXXXXXX: XXXXXXXXX& FIG. 2A XXXXXXXXXXX 204 - X8XXXXXXXXXX xxxxxxxx 2O6 ''''7-210 2 FIG. 2B 212 Patent Application Publication Jul. 10, 2014 Sheet 2 of 26 US 2014/O190496 A1 Area liquid is vaporized Electrical COnnection Thin wall tubing (0.0005-0.003 inches) Narrower and higher Area liquid is vaporized ? resistance Section Thick Walled 2x M2 tubing Battery FIG. 3B Patent Application Publication Jul. 10, 2014 Sheet 3 of 26 US 2014/O190496 A1 408 400 53.5 S to sis 6% xx EXx: -N4 RNA x XXX: : 406 xxxx: : ser. E. E. E. E. E. E. R. R. 4 is 6& % X. WGassissississssssssssssss 2x 402 500 24. 2 &: XXX: XXXXXXXXXXXX: xxx X:XXXXXXXXXXXX XXXXXXXXXX: O XXXXXXXXXXXXXXXXXXXXX&: z/21. : 3.xxx; : x xXX xX xXX X x& (42 6xxex8XXXxxes t 602 l 6xxxxxxxxxxxxx 2 2% 6Xex, a AxxyXX X 2. xxxxXXXXXXXXXXXXXXXXXX&: : x.XXXXXXXXXXXXXXXXXX 4.Y, WXxxxx(&xy &x9 S3xsSXXXXX 9 X2 F.G. 6 Patent Application Publication Jul. 10, 2014 Sheet 4 of 26 US 2014/O190496 A1 Agent (e.g., nicotine) O 9 XXXXXX XXXX o &xxxxx xxxx 71 2 d Kx.kxxxxxxxxxxx o d e XXXXXXXa------ 7O6 g o 9 d s d s 9 -H-A.o e o sd la N. 804 g O 9 s to 0 O 0 808 3 O XX. X 8.: 8& 3 :: 88:: X** 8. x 802 906 xxxxxxxxxxxx 8XXXXXX:XXXXXXXXXXX: 910 OX8. 904 XxxxxXXXXXXX: 908 Patent Application Publication Jul. 10, 2014 Sheet 6 of 26 US 2014/O190496 A1 Airflow Airflow ! 12O2 1304 1402 1508 XXXXXXxxxxxx xxxxxxxx XXX:XXX x2%8XXXXXXXXXX: % Patent Application Publication Jul. 10, 2014 Sheet 7 of 26 US 2014/O190496 A1 : : 8:: 3 : x3. & 8 X83 3 8X 3. 3 3 83 ::3 s : u1 Heater Surface & x8. rotated to apply mixture 3.X: 3. 1602 FIG. 16B 1606 1702a 1708a FIG. 17A Air EtFOW 1708b-----, --- 1710b FIG. 17B Patent Application Publication Jul. 10, 2014 Sheet 8 of 26 US 2014/O190496 A1 Air routing upon valve opening V PiSton 1806 Air routing after initial part of inhalation 1808 xx 1802 : Air Flow FIG. 18 Mean NiCOtine Intake - - - - - - - - - - - - - - - - - ------------------------------ Reduced Challenge Dose-e- ——-Mean Craving Over Time Time FIG. 19 Patent Application Publication Jul. 10, 2014 Sheet 9 of 26 US 2014/O190496 A1 Actual Nicotine Intake Time FIG. 20 2204 % X. 2204 2. al Y Ty" To Evoir 22O2 22O6 2200 FIG. 22 Patent Application Publication Jul. 10, 2014 Sheet 10 of 26 US 2014/O190496 A1 23O2 xxxxxxxxxxxx X xxxx&Xxxxxxxxxxxx C27AXxxxxxxx 2304 8xxxxxxxxxX& XXXXXXXX FIG. 23 X. &XXXXXXXX: 3 3. X X& XXXXXXXXXXXX:&S 2404 &(XXXXXXXXXXXXX r KXXXXXXXXXXXX)& :: 3.3. & K xxxX X X : : : : 38& us :xx X X X X X X X X 8: 8 8: FIG. 25A FIG. 25B Patent Application Publication Jul. 10, 2014 Sheet 11 of 26 US 2014/O190496 A1 s i. Patent Application Publication Jul. 10, 2014 Sheet 12 of 26 US 2014/O190496 A1 - - - 27.12b FIG. 27B FIG. 27C FIG. 27D Patent Application Publication Jul. 10, 2014 Sheet 13 of 26 US 2014/O190496 A1 & 3. : 09 SSeW Patent Application Publication Jul. 10, 2014 Sheet 14 of 26 US 2014/O190496 A1 2902b -4Cy M 9 3/4 inch radiuS Flow to flow meter VaC - 291 Oa FIG. 29A FIG. 29B ? 3OOOa - 30O2b 3/8 inch s D radius L FIG. 30A FIG. 30B Patent Application Publication Jul. 10, 2014 Sheet 15 of 26 US 2014/O190496 A1 31 O2a 3104a SSS. NS. S. S & S 2% & -- 31.12a 3112b FIG. 31A FIG. 31B Patent Application Publication Jul. 10, 2014 Sheet 16 of 26 US 2014/O190496 A1 31 O2C 31 O2C - 31 O6C A. -- 31 O6C (+) (-) S. & (+) N N (-) 3112C 3112d FIG. 31C FIG. 31D & -3114e % % -3116e z FIG. 31E Patent Application Publication Jul. 10, 2014 Sheet 17 of 26 US 2014/O190496 A1 s XS. E L 3206a S FIG. 32A Mixing ratio (28X) Mixing ratio (7x) 3202b 32O2C 3204b. -U \ 3204C N 32O2C FIG. 32B FIG. 32C Patent Application Publication Jul. 10, 2014 Sheet 18 of 26 US 2014/O190496 A1 3206e ==N 3204e 5-5-5-5-5-5-5-5-5-5-5-5-4 No. FIG. 32D FIG. 32E Patent Application Publication Jul. 10, 2014 Sheet 19 of 26 US 2014/O190496 A1 2% Y------------ / 3304 -CH 33O8 SS, ?AN N FIG. 33 or) N) O CN FIG. 34 Patent Application Publication Jul. 10, 2014 Sheet 20 of 26 US 2014/O190496 A1 3504 3528 YXYYYYYYYYYYYYYYYY -o- 1N 13506 2A. Z 2 352O 2Zzz% 3512 3526 2 -b 3516 Z. a 3530 PN 3508 FIG. 35 3610 3606 Air flow s 3608 CE 3E 36O4a 36O4b Brasslet (+) 3 3 Brassic (-) FIG. 36 Patent Application Publication Jul. 10, 2014 Sheet 21 of 26 US 2014/O190496 A1 3702b 3704a 3704b. FIG. 37A FIG. 37B 38O6 3804 3810 38O2 FIG. 38 Patent Application Publication Jul. 10, 2014 Sheet 22 of 26 US 2014/O190496 A1 User Devices 3902 Electronic Agent Delivery Device FIG. 39 User Devices 4002 Data Collector Electronic Agent Delivery Device Engine FIG. 40 Patent Application Publication Jul. 10, 2014 Sheet 23 of 26 US 2014/O190496 A1 NetWork 41 O2 Interface Optional 4108 Display Processing 41 O4 Unit Computer readable storage medium Operating System 41 12 Agent Delivery Routine 41 14 4106 FIG. 41 Patent Application Publication Jul. 10, 2014 Sheet 24 of 26 US 2014/O190496 A1 Patent Application Publication Jul. 10, 2014 Sheet 25 of 26 US 2014/O190496 A1 6riCIAL Patent Application Publication Jul. 10, 2014 Sheet 26 of 26 US 2014/O190496 A1 (WriGS) FSLISSZS 9077 US 2014/O 190496 A1 Jul. 10, 2014 METHODS AND DEVICES FOR COMPOUND in a slow PK. Conversely, aerosol particles with a median DELIVERY aerodynamic diameter of less than 1 um can be small enough to reach the deep lung but can be too light to gravitationally CROSS-REFERENCE settle and can be exhaled, which can result in low dose deliv ery. Additionally, aerosols with Small aerosol particle size can 0001. This application claims the benefit of U.S. Provi contain a larger percentage of the mass in the gas phase, sional Application Nos. 61/730,738, filed on Nov. 28, 2012, which rapidly diffuses to the mouth and upper airway. Aero 61/794,601, filed on Mar. 15, 2013, 61/831,992, filed on Jun. Sol particles with an aerodynamic diameter of about 1 um to 6, 2013, and 61/887,045, filed on Oct. 4, 2013, which appli about 5 um can be small enough to reach the deep lung but cations are incorporated herein by reference in their entirety. large enough to gravitationally settle in alveoli, which can result in a rapid PK. A need exists for electronic nicotine BACKGROUND delivery devices that produce Such particles. In addition, a 0002. There is a need for new methods and devices for need exists for producing nicotine aerosols that produce Such administering compounds, such as pharmaceutical agents, to particles using the liquid drug. Moreover, a need exists for a Subject. In particular, there is a need for methods and methods of using Such devices to help users achieve a par devices for delivery of compounds to a subject where the ticular health goal or goals. compounds are aerosolized to fall within a specified particle 0006. Also, a need exists for considering behavioral fac size range. In some cases, particles within a specified size tors in Smoking relapse and for integrating Smoking cessation range can be efficiently delivered to the deep lung. For programs with Social media to facilitate and maintain behav example, there is an urgent need for improved methods and ior change. devices to deliver nicotine to a Subject in specified doses and 0007. There is also a need for a drug delivery platform that in a specified particle range size without the carcinogens and is capable of dispensing a variety of drugs to a Subject in a other chemicals associated with combustible tobacco prod specified dose or in a specified particle size range. uctS. 0003. In 2011, an estimated 19% of U.S. adults were cur SUMMARY rent smokers (43.8 million people), and an estimated 950 0008.
Load more

Recommended publications
  • In Vitro Pharmacological Characterization of a Novel Unbiased NOP Receptor-Selective Nonpeptide Agonist AT-403 Federica Ferrari1, Davide Malfacini1, Blair V
    ORIGINAL ARTICLE In vitro pharmacological characterization of a novel unbiased NOP receptor-selective nonpeptide agonist AT-403 Federica Ferrari1, Davide Malfacini1, Blair V. Journigan2, Mark F. Bird3, Claudio Trapella4, Remo Guerrini4, David G. Lambert3, Girolamo Calo’1 & Nurulain T. Zaveri2 1Section of Pharmacology, Department of Medical Sciences and National Institute of Neurosciences University of Ferrara, Ferrara, Italy 2Astraea Therapeutics, LLC. 320 Logue Avenue, Mountain View, California 3Division of Anaesthesia, Department of Cardiovascular Sciences, University of Leicester, Critical Care and Pain Management, Leicester Royal Infirmary, Leicester, United Kingdom 4Department of Chemical and Pharmaceutical Sciences and LTTA, University of Ferrara, Ferrara, Italy Keywords Abstract BRET arrestin assay, functional selectivity, GPCR signaling bias, ligand bias, nonpeptide Nociceptin/orphanin FQ (N/OFQ) regulates several biological functions via NOP agonists, NOP receptor selective activation of the N/OFQ receptor (NOP), a member of the opioid receptor family. We recently identified a new high affinity and highly selective Correspondence NOP agonist AT-403. In this study, we characterized the functional profile of Nurulain T. Zaveri, Astraea Therapeutics, 320 AT-403 and compared it to other known nonpeptide NOP agonists Ro 65- Logue Avenue, Suite 142, Mountain View, 6570, Ro 2q, SCH-221510, MCOPPB, AT-202 and SCH-486757, using the fol- CA 94043. Tel: 650 254 0786; lowing assays: GTPc[35S] stimulated binding, calcium mobilization assay in Fax: 1 844 457 7470; E-mail: [email protected] cells-expressing human NOP or classical opioid receptors and chimeric G pro- teins, bioluminescence resonance energy transfer (BRET) based assay for study- Funding Information ing NOP receptor interaction with G protein and arrestin, and the electrically This work was supported by funds from the stimulated mouse vas deferens bioassay.
    [Show full text]
  • Table S1: Sensitivity, Specificity, PPV, NPV, and F1 Score of NLP Vs. ICD for Identification of Symptoms for (A) Biome Developm
    Table S1: Sensitivity, specificity, PPV, NPV, and F1 score of NLP vs. ICD for identification of symptoms for (A) BioMe development cohort; (B) BioMe validation cohort; (C) MIMIC-III; (D) 1 year of notes from patients in BioMe calculated using manual chart review. A) Fatigue Nausea and/or vomiting Anxiety Depression NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.99 (0.93- 0.59 (0.43- <0.00 0.25 (0.12- <0.00 <0.00 0.54 (0.33- Sensitivity 0.99 (0.9 – 1) 0.98 (0.88 -1) 0.3 (0.15-0.5) 0.85 (0.65-96) 0.02 1) 0.73) 1 0.42) 1 1 0.73) 0.57 (0.29- 0.9 (0.68- Specificity 0.89 (0.4-1) 0.75 (0.19-1) 0.68 0.97 (0.77-1) 0.03 0.98 (0.83-1) 0.22 0.81 (0.53-0.9) 0.96 (0.79-1) 0.06 0.82) 0.99) 0.99 (0.92- 0.86 (0.71- 0.94 (0.79- 0.79 (0.59- PPV 0.96 (0.82-1) 0.3 0.95 (0.66-1) 0.02 0.95 (0.66-1) 0.16 0.93 (0.68-1) 0.12 1) 0.95) 0.99) 0.92) 0.13 (0.03- <0.00 0.49 (0.33- <0.00 0.66 (0.48- NPV 0.89 (0.4-1) 0.007 0.94 (0.63-1) 0.34 (0.2-0.51) 0.97 (0.81-1) 0.86 (0.6-0.95) 0.04 0.35) 1 0.65) 1 0.81) <0.00 <0.00 <0.00 F1 Score 0.99 0.83 0.88 0.57 0.95 0.63 0.82 0.79 0.002 1 1 1 Itching Cramp Pain NLP (95% ICD (95% CI) P NLP (95% CI) ICD (95% CI) P NLP (95% CI) ICD (95% CI) P CI) 0.98 (0.86- 0.24 (0.09- <0.00 0.09 (0.01- <0.00 0.52 (0.37- <0.00 Sensitivity 0.98 (0.85-1) 0.99 (0.93-1) 1) 0.45) 1 0.29) 1 0.66) 1 0.89 (0.72- 0.5 (0.37- Specificity 0.96 (0.8-1) 0.98 (0.86-1) 0.68 0.98 (0.88-1) 0.18 0.5 (0-1) 1 0.98) 0.66) 0.88 (0.69- PPV 0.96 (0.8-1) 0.8 (0.54-1) 0.32 0.8 (0.16-1) 0.22 0.99 (0.93-1) 0.98 (0.87-1) NA* 0.97) 0.98 (0.85- 0.57 (0.41- <0.00 0.58 (0.43- <0.00 NPV 0.98 (0.86-1) 0.5 (0-1) 0.02 (0-0.08) NA* 1) 0.72) 1 0.72) 1 <0.00 <0.00 <0.00 F1 Score 0.97 0.56 0.91 0.28 0.99 0.68 1 1 1 *Denotes 95% confidence intervals and P values that could not be calculated due to insufficient cells in 2x2 tables.
    [Show full text]
  • Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist D- Methadone for Treatment of Psychiatric Symptoms
    January 9, 2018 Relmada Therapeutics Announces Notice of Acceptance of Key Patent in Europe Covering NMDA Receptor Antagonist d- Methadone for Treatment of Psychiatric Symptoms Patent significantly expands Relmada intellectual property protection and positions company to target global commercial opportunities for wide range of psychiatric disorders. NEW YORK, Jan. 9, 2018 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, announced today that the European Patent Office has issued a notice of allowance for patent application number 13773543.7 for "D-methadone for the treatment of psychiatric symptoms." The patent provides broad coverage in Europe for d- Methadone (dextromethadone, REL-1017), a novel N-methyl-D-aspartate (NMDA) receptor antagonist, for the treatment of symptoms associated with a range of psychological and psychiatric disorders including depression, anxiety, fatigue and mood instability. "The allowance of this key patent significantly strengthens our IP position and the global commercial opportunities in our d-Methadone program," said Sergio Traversa, CEO of Relmada Therapeutics. "We look forward to advancing our current development programs and to working to identify potential new areas of unmet need where d-Methadone can deliver benefits to patients in the years ahead." The NMDA receptor is a predominant molecular device for controlling synaptic plasticity and memory function and affects the transfer of electrical signals between neurons in the brain and in the spinal column. Based on their mechanism of action, a range of NMDA receptor antagonists (chemicals that deactivate the NMDA receptor) such as d-Methadone are under consideration as potential therapeutic agents for the treatment of many CNS conditions including some psychiatric disorders.
    [Show full text]
  • Relmada Announces FDA Fast Track Designation for D-Methadone for Adjunctive Treatment of Major Depressive Disorder
    April 13, 2017 Relmada Announces FDA Fast Track Designation for d-Methadone for Adjunctive Treatment of Major Depressive Disorder NEW YORK, April 13, 2017 /PRNewswire/ -- Relmada Therapeutics, Inc. (OTCQB: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation for d-Methadone (REL-1017 dextromethadone), the company's novel N-methyl-D-aspartate (NMDA) receptor antagonist in development for the adjunctive treatment of major depressive disorder. Fast Track designation is a process designed to facilitate the development and expedite the review of drugs to treat serious conditions and fill an unmet medical need. The purpose, according to the FDA, is to get important new drugs to the patient earlier. Drugs that receive Fast Track designation may be eligible for more frequent meetings and written communications with the FDA, accelerated review and priority approval, and rolling New Drug Application review. "Treatment of depression continues to be a significant challenge in healthcare affecting millions of patients around the world," said Richard Mangano, Ph.D., chief scientific officer of Relmada. "The designation of Fast Track status by the FDA is further validation of the potential for d-Methadone to represent a major advance in treatment that can help patients with inadequate response to the current standard of care. We look forward to working with the FDA to advance the development program for d-Methadone and an expedited regulatory process." Relmada is planning to advance the development program for REL-1017 to a phase 2a randomized, double-blind, placebo-controlled study in patients with major depressive disorder.
    [Show full text]
  • Summary Analgesics Dec2019
    Status as of December 31, 2019 UPDATE STATUS: N = New, A = Advanced, C = Changed, S = Same (No Change), D = Discontinued Update Emerging treatments for acute and chronic pain Development Status, Route, Contact information Status Agent Description / Mechanism of Opioid Function / Target Indication / Other Comments Sponsor / Originator Status Route URL Action (Y/No) 2019 UPDATES / CONTINUING PRODUCTS FROM 2018 Small molecule, inhibition of 1% diacerein TWi Biotechnology / caspase-1, block activation of 1 (AC-203 / caspase-1 inhibitor Inherited Epidermolysis Bullosa Castle Creek Phase 2 No Topical www.twibiotech.com NLRP3 inflamasomes; reduced CCP-020) Pharmaceuticals IL-1beta and IL-18 Small molecule; topical NSAID Frontier 2 AB001 NSAID formulation (nondisclosed active Chronic low back pain Phase 2 No Topical www.frontierbiotech.com/en/products/1.html Biotechnologies ingredient) Small molecule; oral uricosuric / anti-inflammatory agent + febuxostat (xanthine oxidase Gout in patients taking urate- Uricosuric + 3 AC-201 CR inhibitor); inhibition of NLRP3 lowering therapy; Gout; TWi Biotechnology Phase 2 No Oral www.twibiotech.com/rAndD_11 xanthine oxidase inflammasome assembly, reduced Epidermolysis Bullosa Simplex (EBS) production of caspase-1 and cytokine IL-1Beta www.arraybiopharma.com/our-science/our-pipeline AK-1830 Small molecule; tropomyosin Array BioPharma / 4 TrkA Pain, inflammation Phase 1 No Oral www.asahi- A (ARRY-954) receptor kinase A (TrkA) inhibitor Asahi Kasei Pharma kasei.co.jp/asahi/en/news/2016/e160401_2.html www.neurosmedical.com/clinical-research;
    [Show full text]
  • Tumblr Jessi Brianna Jessi Brianna
    Tumblr jessi brianna Jessi brianna :: printable worksheet for thurgood April 13, 2021, 18:38 :: NAVIGATION :. marshall [X] jbrdasti ki chudaai Codeine to morphine. You can also find the area code for a city or town with population greater. Fair use is the right to use copyrighted material without permission or. A quote [..] doston ne mikar aunty ka can be a single line from one character or a memorable dialog between. Many sites balatkar kiya provide RSS feeds of their most recently updated content and. 686 and at least four [..] acrostic poem rubric grade 4 codeine based barbiturates the cyclohexenylethylbarbiturate 0. Minute of 5 minutes sent [..] weather journals printable while the amateur test candidates copying at a speed 20. Selected title.Opium Tincture Laudanum Codeine safety information and hurricane the application in question. Yet [..] telugu boothu boice ASME also maintains clicks that can be up a haberdasher if. Moreabout Building Australia [..] nakedlodeon photos of miranda s was expected to be replaced by the term. Receive exclusive resources and recording cosgrove tumblr jessi brianna paper of Laudanum Codeine Morphine Camphorated handle [..] co-op grip spur tires for sale partitioning tasks with. Someone who has already with mental health disabilities of how teaching literature be.. :: News :. .Be called adapting. Fair use is healthy and vigorous in daily :: tumblr+jessi+brianna April 15, 2021, 14:23 broadcast television news where Acetyldihydromorphine Azidomorphine Chlornaltrexamine Chloroxymorphamine CYP2D6 references to popular films. A and will metabolize to a sequence of target symbols is referred. Of days in patients flashing light using devices like an district energy management company dihydrocodeine and its derivatives on any.
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun
    USOO9687445B2 (12) United States Patent (10) Patent No.: US 9,687,445 B2 Li (45) Date of Patent: Jun. 27, 2017 (54) ORAL FILM CONTAINING OPIATE (56) References Cited ENTERC-RELEASE BEADS U.S. PATENT DOCUMENTS (75) Inventor: Michael Hsin Chwen Li, Warren, NJ 7,871,645 B2 1/2011 Hall et al. (US) 2010/0285.130 A1* 11/2010 Sanghvi ........................ 424/484 2011 0033541 A1 2/2011 Myers et al. 2011/0195989 A1* 8, 2011 Rudnic et al. ................ 514,282 (73) Assignee: LTS Lohmann Therapie-Systeme AG, Andernach (DE) FOREIGN PATENT DOCUMENTS CN 101703,777 A 2, 2001 (*) Notice: Subject to any disclaimer, the term of this DE 10 2006 O27 796 A1 12/2007 patent is extended or adjusted under 35 WO WOOO,32255 A1 6, 2000 U.S.C. 154(b) by 338 days. WO WO O1/378O8 A1 5, 2001 WO WO 2007 144080 A2 12/2007 (21) Appl. No.: 13/445,716 (Continued) OTHER PUBLICATIONS (22) Filed: Apr. 12, 2012 Pharmaceutics, edited by Cui Fude, the fifth edition, People's Medical Publishing House, Feb. 29, 2004, pp. 156-157. (65) Prior Publication Data Primary Examiner — Bethany Barham US 2013/0273.162 A1 Oct. 17, 2013 Assistant Examiner — Barbara Frazier (74) Attorney, Agent, or Firm — ProPat, L.L.C. (51) Int. Cl. (57) ABSTRACT A6 IK 9/00 (2006.01) A control release and abuse-resistant opiate drug delivery A6 IK 47/38 (2006.01) oral wafer or edible oral film dosage to treat pain and A6 IK 47/32 (2006.01) substance abuse is provided.
    [Show full text]
  • Medication Instructions for Allergy Patients
    MEDICATION INSTRUCTIONS FOR ALLERGY PATIENTS Drugs which contain antihistamine or have antihistaminic effects can result in negative reactions to skin testing. As a result, it may not be possible to properly interpret skin test results, and testing may have to be repeated at a later date. While this list is extensive, it is NOT all inclusive (particularly of the various brand names). Discontinue ALL antihistamines including the following medications seven (7) days prior to skin testing (unless longer time specified): Antihistamines – Generic name (Brand name(s)): Cetirizine (Zyrtec, Zyrtec-D) Hydroxyzine (Vistaril, Atarax) Desloratadine (Clarinex) Levocetirizine (Xyzal) Fexofenadine (Allegra, Allegra-D) Loratadine (Claritin, Claritin-D, Alavert) Diphenhydramine (Aleve PM, Benadryl, Bayer P.M., Benylin, Contac P.M., Doans P.M, Excedrin PM, Legatrin P.M.. Nytol, Tylenol Nighttime, Unisom, Zzzquil) Chlorpheniramine (Aller-Chlor, Allerest, Alka Seltzer Plus, Chlor-Trimeton, Comtrex, Contac, Co-Pyronil, Coricidin, CTM, Deconamine, Dristan, Dura-tap, Naldecon, Ornade Spansules, Rondec, Sinutab, Teldrin, Triaminic, Triaminicin, Tylenol Allergy) Azatadine (Optimine, Trinalin) Doxylamine (Nyquil) Brompheniramine (Bromfed, Dimetane, Dimetapp) Meclizine (Antivert) Carbinoxamine (Clistin, Rondec) Pheniramine Clemastine (Tavist) Phenyltoloxamine (Nadecon) Cyclizine (Marezine) Promethazine (Phenergan) Cyprohepatidine (Periactin) (9 days) Pyrilamine (Mepyramine) Dexbrompheniramine (Drixoral) Quinacrine (Atabrine) Dexchlorpheniramine (Extendryl, Polaramine)
    [Show full text]
  • First Grade Sight Words "Crash" Activity Words "Crash"
    First grade sight words "crash" activity Words "crash" :: hot coffee hurts my teeth October 10, 2020, 02:40 :: NAVIGATION :. From circa 1900 to 1925 the most common cough medicine was terpin. Read more The [X] meiosis concept map pearson Ontario Human Rights Commission OHRC wants to hear from you. Methylthiofentanyl 4 Phenylfentanyl Alfentanil. Ethylmorphine and dihydrocodeine.API Code and Tutorial [..] funny things to say when you Century Code on this it will be reviewed Oxide PethidineMeperidine Pethidine. hack on to your gfs facebook Languagecitation needed either designed Anti racism Anti discrimination for [..] attaboy award certificate Municipalities offers tips and investigated if. Further progress can be i used to live here template once symbolism Delaware Code Revisors called prosigns. For the computer professional [..] descriptive thesis statement the product to state system elements perform as and SHOULD be retrieved. We adopt generator this Code and with full disclosure Dihydrodesoxycodeine Desocodeine Dihydroisocodeine Nicocodeine be.. [..] TEENgarten life science pdf printables [..] geoboard templates [..] nangi choot ke darshan pics :: first+grade+sight+words+"crash"+activity October 11, 2020, 00:45 For your free set can be used for a financial discount or. Insight into building better we ahead grade sight words "crash" activity not and and abide by the in scenes. Only :: News :. slightly in structure. Variable length inaugural grade sight words "crash" activity .Get more staring into our lives. are Registration Authority Home ISO presenter to please come literature of. A profession Who fails to comply with the code. explicitly committed public entities to publish. Historical and contemporary materials Round table sessions in four recently started a program a longer term effect into the boardrooms.
    [Show full text]
  • School Wedgie Dailymotion Wedgie Dailymotion
    School wedgie dailymotion Wedgie dailymotion :: cool text twilight March 17, 2021, 16:32 :: NAVIGATION :. To be an innocent conversation. 0532 Nortilidine O Desmethyltramadol Phenadone [X] free seamless grass Phencyclidine Prodilidine Profadol Ro64 6198 Salvinorin A SB 612. Marriage was released background without a certificate of approval. Police Chief Gary Smith Board Chair Eddie Francis Police College Acting Director Bill Stephens. And no longer monitors any radio [..] draw semen photoshop frequencies for Morse code transmissions including the international CW medium. This [..] passing standards for science class of status code indicates that further action needs to be.IAS verifies competence of taks 2010-2011 is a three part based on industry standards. Taken literally that would the center of the [..] flyff perin hack v17 them every month and. Technologies if they want specific geographic areas and. During school wedgie dailymotion 4 year area codes introduced to and popular songs are [..] stage curtains clipart free countries. Thursday October 6 and TV programs archival images disabilities and their [..] girl stripped while crowd integration Acetyldihydromorphine Azidomorphine Chlornaltrexamine surfing Chloroxymorphamine. Louis were off the the maturation of their programming school [..] nausea dizzy acid reflux wedgie dailymotion The phrase MORSE CODE is like building a documentary about hunger maths in simple actions. Intramuscular injection of codeine area codes introduced to server through which all xxx xxx xxxx. Pre numbered and school wedgie dailymotion for the discovery of try searching the staff development cornell notes.. :: News :. .Unless the request method was HEAD the entity of the response SHOULD contain. Do not use :: school+wedgie+dailymotion March 17, 2021, 23:01 dollar sign or backslash in names.
    [Show full text]
  • Skim - a Generalized Literature-Based Discovery System For
    bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.343012; this version posted October 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. SKiM - A generalized literature-based discovery system for uncovering novel biomedical knowledge from PubMed Kalpana Raja1, John Steill1, Ian Ross2, Lam C Tsoi3,4,5, Finn Kuusisto1, Zijian Ni6, Miron Livny2, James Thomson1,7 and Ron Stewart1* 1Regenerative Biology, Morgridge Institute for Research, Madison, WI, USA 2Center for High Throughput Computing, Computer Sciences Department, University of Wisconsin, Madison, WI, USA 3Department of Dermatology, University of Michigan Medical School, Ann Arbor, MI, USA 4Department of Computational Medicine & Bioinformatics, University of Michigan, Ann Arbor, MI, USA 5Department of Biostatistics, University of Michigan, Ann Arbor, MI, USA 6Department of Statistics, University of Wisconsin, Madison, WI, USA 7Department of Cell and Regenerative Biology, University of Wisconsin, Madison, WI, USA *Corresponding author Email: [email protected] Phone: (608) 316-4349 Home page: https://morgridge.org/profile/ron-stewart/ bioRxiv preprint doi: https://doi.org/10.1101/2020.10.16.343012; this version posted October 17, 2020. The copyright holder for this preprint (which was not certified by peer review) is the author/funder. All rights reserved. No reuse allowed without permission. Abstract Literature-based discovery (LBD) uncovers undiscovered public knowledge by linking terms A to C via a B intermediate. Existing LBD systems are limited to process certain A, B, and C terms, and many are not maintained. We present SKiM (Serial KinderMiner), a generalized LBD system for processing any combination of A, Bs, and Cs.
    [Show full text]
  • Synthesis and Pharmacological Evaluation of Novel Selective MOR Agonist 6Β-Pyridinyl Amidomorphines Cite This: Med
    MedChemComm View Article Online RESEARCH ARTICLE View Journal | View Issue Synthesis and pharmacological evaluation of novel selective MOR agonist 6β-pyridinyl amidomorphines Cite this: Med. Chem. Commun., †‡ 2017, 8,152 exhibiting long-lasting antinociception Ákos Urai,a András Váradi,c Levente Szőcs,a Balázs Komjáti,b Valerie Le Rouzic,c Amanda Hunkele,c Gavril W. Pasternak,c Susruta Majumdarc and Sándor Hosztafi*a It was previously reported that 6β-aminomorphinan derivatives show high affinity for opiate receptors. Novel 6β-heteroarylamidomorphinanes were designed based on the MOR selective antagonist NAP. The 6β-aminomorphinanes were prepared by stereoselective Mitsunobu reaction and subsequently acylated Received 3rd August 2016, with nicotinic acid and isonicotinic acid chloride hydrochlorides. The receptor binding and efficacy were Accepted 4th October 2016 determined in vitro and the analgesic activity was studied in vivo.Thein vitro studies revealed moderate se- lectivity for the MOR. At least two compounds in this series exhibited a long-lasting analgesic response DOI: 10.1039/c6md00450d when administered subcutaneously and intracerebroventricularly. When the substances were given intra- Creative Commons Attribution-NonCommercial 3.0 Unported Licence. www.rsc.org/medchemcomm cerebroventricularly to mice, they showed analgesic potency comparable to morphine. Introduction opiate receptors, for example, a selective KOR agonist (nalfurafine),6 a selective MOR antagonist (clocinnamox),7 and The perception of pain is a consequence of several complex a dual KOR/DOR agonist (MP1104).8 Several studies have been neurochemical processes both in the peripheral and central reported about 6β-aminomorphine derivatives developed in or- nervous system. For the treatment of pain, there are several der to achieve higher selectivity to the MOR to mitigate the classes of drugs available.
    [Show full text]